TERN-601 is under clinical development by Terns Pharmaceuticals and currently in Phase I for Obesity. According to GlobalData, Phase I drugs for Obesity have a 59% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TERN-601’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TERN-601 overview

TERN-601 is under development for the treatment of obesity. The small molecule acts by targeting the GLP-1 receptor. The drug candidate is administered through oral route.

It was under development for metabolic dysfunction-associated steatohepatitis (MASH).

Terns Pharmaceuticals overview

Terns Pharmaceuticals is a biopharmaceutical company that develops single-agent and combination drugs targeting non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The company products pipeline includes TERN- 701, TERN-501 +/- FXR, TERN-601 and TERN-800 series. Its TERN-701 is used in chronic myeloid leukemia; TERN-601 is used in the treatment of obesity and TERN-501 is used in fixed-dose combinations for NASH treatment. It operates offices in the US. Terns Pharmaceuticals is headquartered in Foster City, California, the US.

For a complete picture of TERN-601’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.